Novartis

Novartis announced today that it broke ground on its more than 700,000-square-foot flagship manufacturing hub in North Carolina. The company said it is rapidly moving to construct its recently announced $771 million investment in the state. Its project features a new facility in Morrisville and a new site in Durham, encompassing two new facilities. The…

Novartis announced today that it opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in California. The state-of-the-art site in Carlsbad marks the latest milestone in the company’s previously announced $23 billion investment in U.S. infrastructure over the next five years. Novartis says the Carlsbad facility opening allows it to seamlessly meet future demand for…

Novartis announced today that it plans to invest $23 billion over five years to expand its U.S.-based infrastructure. The company said its investment aims to ensure all key Novartis medicines for U.S. patients will be made in the U.S. Its financial commitment enables the company to expand on its current pharmaceutical manufacturing, research and technology…

Siemens Healthineers announced today that it completed the acquisition of Advanced Accelerator Applications Molecular Imaging from Novartis. The newly acquired unit is a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. According to a news release, it will be known as “Advanced Accelerator Applications, a Siemens Healthineers company.” Reports first…

Pharma giants Sanofi and Novartis came in at No. 7 and 17, respectively, in Time magazine’s “Most Sustainable Companies of 2024” rankings. Overall, nearly 40 of the 500 companies on the list fell under the category of Chemicals, Drugs & Biotechnology. Other large pharma companies making it into the top half of the 500 included…

Novartis announced last week that it broke ground on a biopharmaceutical manufacturing plant in Singapore. The company put forward a $256 million investment to begin the project, which will lead to the deployment of digital and automation solutions to enhance manufacturing productivity, improve operational efficiency, and upskill the workforce. Novartis said this site will focus…

Novartis today announced the expansion of its radioligand therapy (RLT) manufacturing capabilities with a new facility in Indianapolis. The Basil, Switzerland–based pharma giant said it has received FDA approval for commercial manufacturing in Indianapolis of its RLT therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat advanced metastatic prostate cancer. The new 70,000-square foot facility…

The pharmaceutical trend toward increasing concentration appears to be gaining momentum. On September 15, Novartis shareholders approved the company’s proposed spinoff of Sandoz, the generics and biosimilars unit. The company anticipates the deal to close in early October. Similarly, Sanofi is also taking a scalpel to its operations, offloading a selection of its central nervous…

Despite a temporary slowdown during the early days of the pandemic, the pharma sector has witnessed a steady rise in M&A activity over the years. The number of deals climbed from 23 in 2018 to 43 in 2022. Major players driving this trend include Sanofi, Merck & Co. and Novartis. Those three players have made…

Novartis has agreed to sell ophthalmology assets to Bausch + Lomb for an upfront payment of $1.75 billion, with potential milestone payments of up to $750 million. The total value of the deal could reach $2.5 billion. Novartis expects the deal to improve their focus more on higher-margin drugs. Under the terms of the deal,…